Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1405816 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29908063 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL1486208 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29401938 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29399772 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29353891 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| Hydrochloric Acid SCHEMBL30912894 | 0.99 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL9596624 | 0.92 | CASP3 (0.49) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL30523593 | 0.92 | MDM4 (0.48) | MDM4TP53MDM2CASP3 | |
| SCHEMBL30718996 | 0.91 | PTPN1 (0.49) | MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114939178-B | Amino acid/polypeptide coordination polymer and preparation method and application thereof | 中国药科大学 | 2024-07-12 | — | — | CN | claimed |
| US-20240174714-A1 | TREATMENT OF SKIN DISORDERS | BACOBA AG (CH) | 2024-05-30 | — | — | US | disclosed |
| US-9257576-B2 | Amino acid generator and polysiloxane composition containing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-9139614-B2 | Modular linkers for conjugation of organic substances to substantially inorganic substances and methods of manufacture and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130313669-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-11-28 | — | — | US | disclosed |
| US-8318717-B2 | Tetrapeptide capable of inhibiting binding of the Smac protein to Inhibitors of apoptosis, thus promoting apoptosis or sensitizing cells; antiproliferative and anticarcinogenic agents | 2CUREX (DK) | 2012-11-27 | — | — | US | disclosed |
| US-20110073977-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-1641795-B1 | TRIAZA- AND TETRAAZA-ANTHRACENEDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20090159842-A1 | MODULAR LINKERS FOR CONJUGATION OF ORGANIC SUBSTANCES TO SUBSTANTIALLY INORGANIC SUBSTANCES AND METHODS OF MANUFACTURE AND USE THEREOF | THE GOVERNMENT OF THE UNITED STATES, AS RESPRESENTED BY THE SECRETARY OF THE NAVY | 2009-06-25 | — | — | US | disclosed |
| WO-2009023320-A2 | MODULAR LINKERS FOR CONJUGATION OF ORGANIC SUBSTANCES TO SUBSTANTIALLY INORGANIC SUBSTANCES AND METHODS OF MANUFACTURE AND USE THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20080194537-A1 | Compounds Modifying Apoptosis | 2CUREX (DK) | 2008-08-14 | — | — | US | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-7132536-B2 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-07 | — | — | US | disclosed |
| EP-1641795-A1 | TRIAZA- AND TETRAAZA-ANTHRACENEDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20040248900-A1 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| WO-2004094425-A1 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | WO | disclosed |
| EP-1471066-A1 | Triaza- and tetraaza-anthracenedione derivates, their preparation and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194537-A1 | Compounds Modifying Apoptosis | API5, BAX, BAD | MDM4 486/4885TP53 32/4885MDM2 165/4885 |
| US-20040248900-A1 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | CYP19A1, TBXAS1, CYP11B1 | MDM4 3885/4885TP53 3837/4885MDM2 4620/4885 |
| US-20110073977-A1 | AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME | DAO, BCAT1, BCAT2 | MDM4 1211/4885TP53 1965/4885MDM2 955/4885 |
| US-20240174714-A1 | TREATMENT OF SKIN DISORDERS | HRH4, NR1H4, NR1H3 | MDM4 3823/4885TP53 4245/4885MDM2 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.